12.71

3.00% 0.37

After Hours: 12.71

Tonix Pharmaceuticals Holding Corp (TNXP)

Overview News Price History Financials Why TNXP Down? Discussions Forecast Stock Split

Tonix Pharmaceuticals Holding Corp stock is traded at $12.71, with a volume of 188.49K. It is up +3.00% in the last 24 hours and up +14.81% over the past month. Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

Previous Close:

$12.34

Open:

$12.28

24h Volume:

188.49K

Relative Volume:

0.38

Market Cap:

$202.61M

Revenue:

$13.11M

Net Income/Loss:

$-124.02M

P/E Ratio:

-0.8912

EPS:

-14.261

Net Cash Flow:

$-107.25M

1W Performance:

-0.31%

1M Performance:

+14.81%

6M Performance:

-17.25%

1Y Performance:

-64.18%

1-Day Range:

$12.11

$12.77

1-Week Range:

$12.11

$12.99

52-Week Range:

$10.03

$69.97

Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile

Name

Tonix Pharmaceuticals Holding Corp

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

212-980-9155

Address

200 CONNELL DRIVE, SUITE 3100, BERKELEY HEIGHTS, NY

Employee

142

Twitter

@TONIXPharma

Next Earnings Date

2026-08-10

Latest SEC Filings

TNXP's Discussions on Twitter

Compare TNXP vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TNXP Tonix Pharmaceuticals Holding Corp	12.71	203.40M	13.11M	-124.02M	-107.25M	-14.26
VRTX Vertex Pharmaceuticals Inc	529.59	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	649.81	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	916.80	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	313.04	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.99	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-18-22	Initiated	Noble Capital Markets	Outperform
Apr-18-19	Upgrade	ROTH Capital	Neutral → Buy
Aug-18-17	Upgrade	ROTH Capital	Neutral → Buy
Sep-07-16	Downgrade	ROTH Capital	Buy → Neutral
Feb-17-16	Reiterated	Oppenheimer	Outperform
Nov-04-15	Initiated	Cantor Fitzgerald	Buy
Jun-12-15	Initiated	Oppenheimer	Outperform
Feb-17-15	Reiterated	ROTH Capital	Buy
Sep-29-14	Reiterated	ROTH Capital	Buy

View All

Tonix Pharmaceuticals Holding Corp Stock (TNXP) Latest News

Jun 30, 2026

Tonix: 'Hold' Based On Tonmya Payer Expansions And MDD Trial Initiation - Seeking Alpha

Jun 30, 2026

Jun 29, 2026

symbol__ Stock Quote Price and Forecast - CNN

Jun 29, 2026

Tonix Pharmaceuticals Holding Corp. has enrolled the first patient in its Phase 2 “HORIZON” study of TNX-102 SL (sublingual tablet) for the treatment of major depressive disorder (MDD). - Bitget

Jun 29, 2026

Tonix: Slow Start For Tonmya, Speculative Pipeline Warrants Hold Rating (NASDAQ:TNXP) - Seeking Alpha

Jun 29, 2026

TNXP Stock Dives For Four Straight Sessions — Retail Eyes Drug Pipeline Payoff - Stocktwits

Jun 27, 2026

Jun 26, 2026

TNXP Slips After Hours On Slower Than Expected Launch For Fibromyalgia Drug - Stocktwits

Jun 26, 2026

Tonix Pharmaceuticals Holding Corp. Actuals & Estimates (DUS:TPM0) - TradingView

Jun 26, 2026

Enterprise value to revenue forward of Tonix Pharmaceuticals Holding Corp. – NASDAQ:TNXP - TradingView

Jun 26, 2026

Tonix Pharmaceuticals Holding Corp. Actuals & Estimates (NASDAQ:TNXP) - TradingView

Jun 26, 2026

Jun 25, 2026

Tonix Pharmaceuticals Holding Corp. Actuals & Estimates (FWB:TPM0) - TradingView

Jun 25, 2026

Price to sales forward of Tonix Pharmaceuticals Holding Corp. – NASDAQ:TNXP - TradingView

Jun 25, 2026

Tonix Pharmaceuticals (TNXP) Receives Strong Buy Rating with $26 Target - GuruFocus

Jun 25, 2026

TNXP Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

TNXP Initiated Coverage by Raymond James -- Price Target Set at $26 - GuruFocus

Jun 25, 2026

This Tonix Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Sahm

Jun 25, 2026

Jun 24, 2026

Raymond James initiates Tonix Pharma stock coverage with strong buy By Investing.com - Investing.com South Africa

Jun 24, 2026

Raymond James initiates Tonix Pharma stock coverage with strong buy - Investing.com

Jun 24, 2026

TNXP Stock Rises Premarket: Investors Cheer Early Traction For Fibromyalgia Drug Despite Weak Q4 Print - Stocktwits

Jun 24, 2026